Assessing Alzheimer’s risk starts with a single blood test

**QUEST AD-Detect™ Amyloid Beta 42/40 Ratio** is analytically validated and less invasive,

More than 6 million Americans are living with Alzheimer’s—and that number is projected to more than double by 2050. Assessing the risk of Alzheimer’s disease has never been more critical.

**Help assess Alzheimer’s risk with a simple, accessible, and affordable blood test**

**QUEST AD-Detect** gives you the diagnostic insights you need to assess the risk of Alzheimer’s disease (AD). Our high-precision assay, using a simple blood sample, is the same type of assay shown to be as effective as traditional cerebrospinal fluid testing and amyloid positron emission tomography (PET) scans. A more accessible and affordable option, plasma testing allows you to establish a baseline and monitor your patients through our 2,100+ Patient Service Center locations.

**Evaluate for Alzheimer’s accurately and reliably with ratio of plasma Aβ42/40**

**QUEST AD-Detect** assists in the differential diagnosis of AD.**1,2**

**QUEST AD-Detect** is a high-precision assay of a type reported in a recently published study to be as effective as traditional methods. Internal preliminary studies at Quest have shown the potential for **QUEST AD-Detect** to be as sensitive as a PET scan.**1,2,4**

**Inform potential treatment decisions**

In addition to providing accessible insights into the risk of AD, **QUEST AD-Detect** blood-based biomarker testing may also help identify patients who are candidates for early antibody treatment.

As new therapies continue to emerge, antibody treatment may help slow disease progression and improve quality of life.

The **QUEST AD-Detect Amyloid Beta 42/40 Ratio** is designed to monitor Aβ 42/40 changes over time to help assess the risk potential of Alzheimer’s disease progression. Initial test results may serve as a baseline with which later test results can be compared. There is no one test that can diagnose AD. Results of the **QUEST AD-Detect** test should be considered in the context of patient management that evaluates symptoms, history, and other factors.
Identify risk and monitor patients longitudinally

Our enhanced report provides Aβ42/40 ratio values from current and 5 past results in 1 table so you can continually monitor your patient’s amyloid Beta ratio as a component of their risk.

- Lower risk of AD: ≥ 0.170
- Intermediate risk of AD: 0.150 to 0.169
- Higher risk of AD: < 0.150

Ordering information

<table>
<thead>
<tr>
<th>Test name</th>
<th>Specimen</th>
<th>Turnaround time</th>
<th>Test code</th>
</tr>
</thead>
<tbody>
<tr>
<td>QUEST AD-Detect Amyloid Beta 42/40 Ratio</td>
<td>Plasma</td>
<td>3 - 10 days</td>
<td>11786</td>
</tr>
</tbody>
</table>

The power of Quest Advanced® Neurology

Innovative solutions, clinical expertise, and improved experiences for better patient outcomes.

- 600+ medical experts who are eager to consult with you on next steps for your patients
- Comprehensive insurer access, serving more than 160 million patients annually
- Over 2100 Patient Service Centers (PSCs), meeting patients where they live and work to ensure access to testing
- Quanum® Solutions, a complete cloud EHR, helps keep practices efficient and patient-focused
- Our MyQuest® digital portal gives your patients the ability to take charge of their personal health journey from any device
- Interface with over 850 EHR systems—making sure you always have seamless access to ordering and results

Learn how Quest is actively working to end Alzheimer’s at QuestForTheCure.com

References:

Image content features a model and is intended for illustrative purposes only.

Test codes may vary by location. Please contact your local laboratory for more information.

QuestDiagnostics.com

Quest, Quest Diagnostics, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—™ and ®—are the property of their respective owners. © 2023 Quest Diagnostics Incorporated. All rights reserved. SB10939 6/2023